Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-finding trial of BI 1569912 as adjunctive therapy in major depressive disorder
jRCT2031240035Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of BI 1569912 in major depressive disorder (MDD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in MADRS total score at Day 8. Started Jul 2024; status: completed.
02
Drugs
BI 1569912
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2031240035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240035.